Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Discov. 2023 Mar 1;13(3):570–579. doi: 10.1158/2159-8290.CD-22-0764

Figure 3. Tumor genomic profiles by sex among patients with early-onset non-hypermutated CRC.

Figure 3.

(A) Boxplot of adjusted mutation rate residuals (tumor mutational burden, TMB) by sex for early-onset and late-onset non-hypermutated CRC. The residual of adjusted mutation rates and P-values were derived from models adjusted for race and ethnicity, tumor site and histology, sequencing assay, and sample type.

(B-C) Mutation frequencies between genes differentially expressed between early-onset vs late-onset non-hypermutated CRC cases that reached statistical significance (P<0.05) for (B) females and (C) males. </p/>(D) Inverse mutation frequencies for EP300 in non-hypermutated CRCs among young patients by sex.